Omnicell (OMCL)
(Real Time Quote from BATS)
$43.70 USD
-0.36 (-0.82%)
Updated Sep 24, 2024 10:06 AM ET
3-Hold of 5 3
B Value A Growth A Momentum A VGM
Company Summary
Headquartered in Mountain View, CA, Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application, and a Web-based procurement application.
The products offered by the company enable care providers to improve patient safety and increase efficiency by lowering costs. The company also adheres to regulatory compliances and addresses issues related to population health.
Omnicell previously ...
Company Summary
Headquartered in Mountain View, CA, Omnicell Inc., develops and markets end-to-end automation solutions for the medication-use process. These automation solutions contain medication and supply dispensing systems, central pharmacy storage, retrieval and packaging solutions, a bedside automation solution, a physician order management solution, a decision support application, and a Web-based procurement application.
The products offered by the company enable care providers to improve patient safety and increase efficiency by lowering costs. The company also adheres to regulatory compliances and addresses issues related to population health.
Omnicell previously had two reporting segments, namely Automation and Analytics, and Medication Adherence. In an effort to deliver on the vision of the autonomous pharmacy and address industry changes (including the ongoing consolidation of healthcare systems, rising pharmaceutical costs and increased scrutiny on controlled substances), Omnicell initiated a company-wide organizational realignment in 2018. It was done to centrally manage business operations, including the development and marketing of all of its products, sales and distribution, supply chain and inventory management, and regulatory and quality functions.
As a result of the organizational realignment, all significant operating decisions are based upon an analysis of Omnicell as one operating segment. Thus, effective Jan 1, 2019, Omnicell reports as only one operating segment, which is the same as the reporting segment.
The company categorizes its offerings under Product and Service and other.
Product Revenues: Comprised 62% of 2023 revenues, down 22% from the 2022 figure. This includes software-enabled connected devices, software licenses, packaging equipment and other supplies. It also includes consumables such as medication adherence packaging, labeling and other one-time-use packaging.
Service and Other Revenues: (38% of 2023 revenues, up 11.7%) This includes post-installation technical support and other related services and Advanced Services.
General Information
Omnicell, Inc
4220 NORTH FREEWAY
FORT WORTH, TX 76137
Phone: 877-415-9990
Fax: 847-596-3402
Email: ir@omnicell.com
Industry | Medical Info Systems |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 6/30/2024 |
Exp Earnings Date | 11/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 0.41 |
Current Year EPS Consensus Estimate | 1.40 |
Estimated Long-Term EPS Growth Rate | 1.40 |
Exp Earnings Date | 11/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 44.06 |
52 Week High | 49.94 |
52 Week Low | 25.12 |
Beta | 0.83 |
20 Day Moving Average | 561,303.38 |
Target Price Consensus | 41.50 |
4 Week | -3.02 |
12 Week | 65.33 |
YTD | 17.09 |
4 Week | -4.74 |
12 Week | 58.29 |
YTD | -2.34 |
Shares Outstanding (millions) | 45.99 |
Market Capitalization (millions) | 2,026.49 |
Short Ratio | NA |
Last Split Date | NA |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 31.42 |
Trailing 12 Months | 29.57 |
PEG Ratio | 22.28 |
vs. Previous Year | 10.34% |
vs. Previous Quarter | 328.57% |
vs. Previous Year | -7.42% |
vs. Previous Quarter | 12.45% |
Price/Book | 1.68 |
Price/Cash Flow | 14.02 |
Price / Sales | 1.88 |
6/30/24 | 2.52 |
3/31/24 | 2.41 |
12/31/23 | 3.43 |
6/30/24 | 1.33 |
3/31/24 | 1.28 |
12/31/23 | 1.81 |
6/30/24 | 2.45 |
3/31/24 | 2.38 |
12/31/23 | 2.52 |
6/30/24 | 2.22 |
3/31/24 | 2.13 |
12/31/23 | 2.22 |
6/30/24 | 2.78 |
3/31/24 | 2.59 |
12/31/23 | 3.50 |
6/30/24 | -1.92 |
3/31/24 | -1.91 |
12/31/23 | -1.78 |
6/30/24 | -1.92 |
3/31/24 | -1.52 |
12/31/23 | -1.75 |
6/30/24 | 26.15 |
3/31/24 | 25.88 |
12/31/23 | 26.15 |
6/30/24 | 6.02 |
3/31/24 | 5.55 |
12/31/23 | 5.22 |
6/30/24 | 0.47 |
3/31/24 | 0.48 |
12/31/23 | 0.48 |
6/30/24 | 32.20 |
3/31/24 | 32.43 |
12/31/23 | 32.39 |